By Fineline Cube 
US-based ProFound Therapeutics announced a four-year partnership with Swiss giant Novartis (NYSE: NVS) to discover novel protein targets in the extended human proteome for cardiovascular drug development. The collaboration leverages ProFound’s proprietary ProFoundry platform.
Partnership Details
ProFound will receive an upfront payment of USD 25 million and near-term milestone payments. The company is also eligible for downstream milestones potentially reaching USD 750 million per target, along with tiered royalties.
ProFoundry Platform
The ProFoundry platform combines multi-omic biological data and advanced computational tools to identify previously overlooked proteins in the extended proteome. These proteins are evaluated as potential drug targets and therapeutic candidates. The collaboration brings together ProFound’s expertise in protein discovery and Novartis’s cardiovascular R&D capabilities to accelerate next-generation therapy development.-Fineline Info & Tech